Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets

This study has been completed.
Sponsor:
Information provided by:
Mylan Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00650520
First received: March 30, 2008
Last updated: March 31, 2008
Last verified: March 2008

March 30, 2008
March 31, 2008
May 2007
July 2007   (final data collection date for primary outcome measure)
Bioequivalence [ Time Frame: within 30 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00650520 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets
Study of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets Following a 10 mg Dose in Healthy Adult Volunteers Under Fed Conditions

The objective of this study is to assess the single-dose relative bioavailability of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 2.5 mg bromocriptine mesylate tablets, following the administration of a 10 mg dose, under fed conditions.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Healthy
  • Drug: BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
    4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
  • Drug: Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
    4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
  • Experimental: 1
    Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL)and BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
    Intervention: Drug: BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
  • Active Comparator: 2
    Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL) and Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
    Intervention: Drug: Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
119
July 2007
July 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy adult male or female volunteers, 18-45 years of age.

    • Subjects will be continuous non-smokers for at least 3 months prior to the first dose or consistent moderate smokers (fewer than 10 cigarettes per day) for at least 3 months prior to the first dosing.
    • Weighing at least 60 kg for males and 52 kg for females and within the normal range, according to accepted normal values of the Body Mass Index chart (BMI) (18.00-28.00 kg/m2).
    • Medically healthy subjects with clinically normal laboratory profiles and 12-lead ECG.
    • Females of childbearing potential should either be sexually inactive (abstinent) for 14 days prior to the first dose and throughout the study or be using one of the following acceptable birth control methods:

      1. surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) 6 months minimum;
      2. IUD (excluding hormone-releasing-IUD) in place for at least 3 months and throughout the study;
      3. barrier methods (condom or diaphragm) with spermicide for at least 14 days prior to the first dose and throughout the study;
      4. surgical sterilization of the partner (vasectomy for 6 months minimum). In addition, female subjects of childbearing potential will be advised to remain sexually inactive or to keep the same birth control method for at least 3 days following the last dose.

Other birth control methods may be deemed acceptable. Postmenopausal women with amenorrhea for at least 2 years will be eligible.

  • Males must use a spermicide-containing barrier method of contraception to prevent the pregnancy of their female sexual partner from screening, throughout the entire study and for at least 3 days following the last dose.
  • Give voluntary written informed consent to participate in the study.

Exclusion Criteria:

  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease.

    • In addition, history or presence of:
    • depression;
    • seizure or history of EEG abnormalities;
    • glaucoma or hypermetropia;
    • frequent migraine episodes;
    • alcoholism or drug abuse within the past year;
    • past psychotic or maniac episodes;
    • asthma, chronic bronchitis or any other bronchospastic conditions;
    • peptic ulcer;
    • hypersensitivity or idiosyncratic reaction to bromocriptine or to any ergot alkaloids related compound;
    • hypersensitivity or idiosyncratic reaction to, acetaminophen, diphenhydramine, metoclopramide, diazepam or any phenothiazines related compound.
    • Subjects who tested positive at screening for HIV, HbsAg or HCV.
    • Subjects whose sitting blood pressure is less than 110/60 mmHg at screening or less than 100/55 mmHg prior to dosing in each period.
    • Subjects whose sitting blood pressure is more than 140/90 mmHg at screening or prior to dosing in each period.
    • Subjects whose pulse is lower than 55 b.p.m. at screening or 50 b.p.m. prior to dosing in each period.
    • Female subjects who are pregnant or lactating.
    • Female subjects who are taking hormonal contraceptives or are on hormonal replacement therapy (this includes all formulation, e.g. oral, transdermal, vaginal) during the 28 days prior to the first dose and throughout the study.
    • Subjects who have used Depo-Provera® or levonorgestrel implant within 90 days prior to the first dose and throughout the study.
    • Subjects who have received any substance with monoamine oxidase inhibitor (MAOI) activity within 28 days prior to the first dose.
    • Subjects who have food allergy, problems of galactose intolerance or glucose-galactose malabsorption, or any restriction that, in the opinion of the Principal Investigator, could contraindicate the subject's participation in the study.
    • Subjects who have been on a special diet (for whatever reason) during the 28 days prior to the first dose and throughout the study.
    • Subjects who donated 50 to 499 mL of blood within 30 days and more than 499 mL within 56 days prior to the first dose.
    • Subjects who, through completion of the study, would have donated in excess of:

      500 mL of blood in 14 days; 1500 mL of blood in 180 days; 2500 mL of blood in 1 year.

    • Subjects who have participated in another clinical trial within 28 days prior to the first dose.
Both
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00650520
BROM-0734
Not Provided
Will Sullvan, Global Head of Product Risk and Safety Management, Mylan Inc.
Mylan Pharmaceuticals
Not Provided
Principal Investigator: Gaetano Morelli, M.D. MDS Pharma Services
Mylan Pharmaceuticals
March 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP